Green Journals

International Approved Journals

Journal Information

Journal Title	GaBI Journal
Publisher	Pro Pharma Communications International
ISSN	2033-6403
E-ISSN	2033-6772
Database	SCOPUS
Domain	Health Sciences, Life Sciences, Physical Sciences, Social Sciences

Classification History

Year	A+	A	B	C
2026			✓	
2025			✓	
2024				
2023			✓	
2021/2022			✓	
2020			✓	
2019			✓	
2018				

Classification: The table above shows all journal classifications recorded for each classification year in the Green Journals database. A journal may have more than one classification in the same year.

Recent Articles

Effective and safe handling of pre-filled syringe (PFS) for administration of biosimilar candidate AVT06 (aflibercept) in patients with chorioretinal vascular diseases
2025-12-15 Vol. 14 Issue 3 Pages 85-92
Authors: Silvia Cirillo, Riken Soni, Masna Rai et al.
DOI: 10.5639/gabij.2025.1403.016

Biosimilars in oncology: beyond regulation—building confidence through evidence and dialogue
2025-12-15 Vol. 14 Issue 3 Pages 73-73
Authors: César Humberto Oyarzo Mansilla
DOI: 10.5639/gabij.2025.1403.013

Australian biosimilar policies not delivering on intended outcomes: where to from here?
2025-12-15 Vol. 14 Issue 3 Pages 93-102
Authors: Chad Rieger, Clint Holland
DOI: 10.5639/gabij.2025.1403.017

Barriers to expanding biosimilars in oncological indications in Chile: A value-chain approach to understand visions and propose recommendations for improving value proposition
2025-12-15 Vol. 14 Issue 3 Pages 75-84
Authors: Daniela Maria Paredes-Fernández, Rony Christian Lenz-Alcayaga
DOI: 10.5639/gabij.2025.1403.015

Rising costs of biologicals: effective cost-containment does not please all stakeholders
2025-12-15 Vol. 14 Issue 3 Pages 74-74
Authors: Pekka Kurki
DOI: 10.5639/gabij.2025.1403.014

Turkey’s biotech manufacturing ambitions: Yerlika Biopharma’s strategic role
2025-8-15 Vol. 14 Issue 2 Pages 63-65
DOI: 10.5639/gabij.2025.1402.010

Biosimilar trial failed? Investors get their money back: a new insurance model redefines clinical trial financing
2025-8-15 Vol. 14 Issue 2 Pages 68-69
Authors: Tomas J Philipson, Dhruva Gupta, Jacob Shia et al.
DOI: 10.5639/gabij.2025.1402.011

Follow-on biologicals/biosimilars approved in Brazil: September 2025 update
2025-8-15 Vol. 14 Issue 2 Pages 47-52
Authors: Sílvia Helena Cestari de Oliveira, German Enrique Wassermann
DOI: 10.5639/gabij.2025.1402.008

Current trends in biosimilar uptake and special focus on automatic substitution – a symposium report
2025-8-15 Vol. 14 Issue 2 Pages 53-62
Authors: Alan Lyles, E Heinonen, HM Tolonen et al.
DOI: 10.5639/gabij.2025.1402.009

A spectrum of generics and biosimilars: research, reports, and interviews
2025-8-15 Vol. 14 Issue 2 Pages 39-39
Authors: Robin Thorpe
DOI: 10.5639/gabij.2025.1402.006